Loading organizations...

§ Private Profile · 10075 Barnes Canyon Rd Suite 100, San Diego, CA 92121
Vividion Therapeutics is a technology company.
Vividion Therapeutics has raised $272.0M across 3 funding rounds.
Key people at Vividion Therapeutics.
Vividion Therapeutics has raised $272.0M in total across 3 funding rounds.
Vividion Therapeutics develops small molecule therapeutics leveraging a covalent-first chemoproteomics platform. This innovative approach enables the discovery and development of drugs targeting historically undruggable disease-causing proteins, significantly expanding the scope of treatable conditions. Their technology focuses on precisely identifying and engaging these difficult protein targets to modulate disease pathways.
Co-founded by Dr. Benjamin Cravatt, a prominent chemical biologist from The Scripps Research Institute, Vividion Therapeutics emerged in 2014. The company was born from the insight that a systematic covalent chemoproteomics strategy could unlock novel small molecule interactions with proteins, offering a more effective pathway to drug discovery beyond conventional methods. Cravatt's expertise underpins this foundational scientific premise.
The company's focus is on patients suffering from devastating diseases, addressing unmet medical needs through their precision therapeutic pipeline. Vividion Therapeutics envisions transforming patient care by making a wider range of disease targets accessible to small molecule intervention, ultimately providing impactful new treatment options where few currently exist.
Key people at Vividion Therapeutics.
Vividion Therapeutics is a clinical‑stage biotechnology company that uses a proprietary chemoproteomics and covalent‑chemistry platform to discover and develop highly selective small‑molecule medicines against previously “undruggable” protein pockets in oncology and immune disorders; it is a wholly owned, independently operated subsidiary of Bayer with headquarters and a major R&D center in San Diego[4][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech and Biopharma Landscape
Quick Take & Future Outlook
Vividion Therapeutics has raised $272.0M across 3 funding rounds. Most recently, it raised $140.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $140M Series C | Aaron Davis, Graham Walmsley | ARCH Venture Partners, Cure Ventures, Earlybird Venture Capital, Versant Ventures, Vivo Capital, Avoro Capital Advisors, BlackRock, BVF Partners, Casdin Capital, Driehaus Capital Management, Mubadala Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates, Woodline Partners | Announced |
| Apr 1, 2019 | $82M Series B | Jakob Loven | ARCH Venture Partners, Canaan Partners, Cure Ventures, Earlybird Venture Capital, Nextech Invest, VenBio Partners, Versant Ventures, Vivo Capital, Alexandria Venture Investments, Altitude Life Science Ventures, BVF Partners, Cardinal Partners, Casdin Capital, Celgene, Mirae Asset Capital, Mubadala Capital, Trinitas Capital | Announced |
| Feb 1, 2017 | $50M Series A | ARCH Venture Partners, Versant Ventures | Cure Ventures, Earlybird Venture Capital, Vivo Capital, John Clarke | Announced |
Vividion Therapeutics has raised $272.0M in total across 3 funding rounds.
Vividion Therapeutics's investors include Aaron Davis, Graham Walmsley, ARCH Venture Partners, Cure Ventures, Earlybird Venture Capital, Versant Ventures, Vivo Capital, Avoro Capital Advisors, BlackRock, BVF Partners, Casdin Capital, Driehaus Capital Management.